Press Releases
Press Releases
-
September 16, 2021
Trodelvy® Significantly Improved Quality of Life Over Standard of Care in 2L+ Metastatic Triple-Negative Breast Cancer in Phase 3 ASCENT Study -
September 16, 2021
New Data Demonstrate Trodelvy® Survival Benefit in Metastatic Triple-Negative Breast Cancer Patients Regardless of Initial HR/HER2 Status -
September 13, 2021
Gilead to Present New Data at ESMO Congress 2021 Reinforcing the Practice-changing Potential of Trodelvy -
September 1, 2021
Gilead Sciences to Present at Upcoming Investor Conference -
August 19, 2021
European Medicines Agency Validates Gilead’s Marketing Authorization Application for Lenacapavir, an Investigational, Long-Acting Capsid Inhibitor for the Treatment of HIV-1 in People With Limited Therapy Options -
August 5, 2021
Kite and Appia Bio Announce Collaboration to Research and Develop Allogeneic Cell Therapies for Cancer -
August 4, 2021
BioNTech Completes Acquisition of Kite’s Neoantigen TCR Cell Therapy R&D Platform and Manufacturing Facility in Gaithersburg, Maryland -
August 3, 2021
Gilead Sciences Endows Its Foundation With More Than $200 Million to Support Health Justice, Community Giving and Employee Match Program -
July 29, 2021
Gilead Sciences Announces Second Quarter 2021 Financial Results -
July 19, 2021
BioNTech to Acquire Kite’s Neoantigen TCR Cell Therapy R&D Platform and Manufacturing Facility in Gaithersburg, MD